FMP
Catabasis Pharmaceuticals, Inc.
CATB
NASDAQ
Inactive Equity
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
8.54 USD
-0.64000034 (-7.49%)
About
ceo
Dr. Jill Milne
sector
Healthcare
industry
Biotechnology
website
http://www.catabasis.com
exchange
NASDAQ
Description
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research In...
CIK
0001454789
ISIN
US14875P2065
CUSIP
14875P206
Address
100 High Street, 28th Floor
Phone
16173491971
Country
US
Employee
20
IPO Date
Jun 25, 2015
Summary
CIK
0001454789
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
14875P206
ISIN
US14875P2065
Country
US
Price
8.54
Beta
1.66
Volume Avg.
528.92k
Market Cap
234.86M
Shares
-
52-Week
8.48-9.21
DCF
16.12
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
http://www.catabasis.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CATB News
It looks like there's no news available.
